Registry for patients with metastatic cancer receiving radiation therapy
UNC Metastatic Cancer Radiation Therapy Registry
This study collects information from patients with metastatic cancer who are getting radiation therapy to see how well it works and improve future treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | UNC Lineberger Comprehensive Cancer Center Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Chapel Hill, North Carolina) |
| Trial ID | NCT06306924 on ClinicalTrials.gov |
What this trial studies
This registry collects clinical data from patients at UNC Hospitals who have metastatic cancer and are being evaluated for radiation therapy as part of their standard treatment. The aim is to create a comprehensive dataset that links clinical data with patient-reported outcomes, facilitating future research on the effectiveness of radiation therapy in metastatic cancer. By analyzing this data, researchers hope to identify correlations between different radiation therapy regimens and patient outcomes, ultimately enhancing treatment strategies.
Who should consider this trial
Good fit: Ideal candidates for this registry are adults aged 18 and older who have been diagnosed with or are suspected to have metastatic cancer and are being evaluated for radiation therapy.
Not a fit: Patients with serious medical or psychiatric disorders that prevent them from providing informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this registry could improve understanding of how radiation therapy impacts outcomes in metastatic cancer patients, leading to better treatment protocols.
How similar studies have performed: While this registry approach is common in cancer research, the specific focus on linking radiation therapy regimens with metastatic cancer outcomes is a valuable and potentially novel contribution to the field.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Written informed consent was obtained to participate in the study and HIPAA Authorization for release of personal health information. Ability to understand and willingness to sign informed consent Diagnosed with or is suspected to have metastatic cancer. Age ≥ 18 years at the time of consent. Evaluated to receive radiation therapy as part of their standard-of-care treatment plan. Exclusion Criteria: All participants must not meet any of the following exclusion criteria prior to enrollment to participate in this study: Any serious medical or psychiatric disorder that would interfere with the participant's ability to give informed consent.
Where this trial is running
Chapel Hill, North Carolina
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill — Chapel Hill, North Carolina, United States (Recruiting)
Study contacts
- Principal investigator: Shivani Sud, MD — UNC Lineberger Comprehensive Cancer Center
- Study coordinator: Kadiata Toumbou
- Email: kadiata@email.unc.edu
- Phone: (202) 569-3721
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.